Castle Biosciences
345 articles about Castle Biosciences
-
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
4/20/2022
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress.
-
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
4/18/2022
Castle Biosciences, Inc. announced a recent poster presentation highlighting data and concluding that its non-invasive skin scraping technique produces sufficient ribonucleic acid to assess reproducible gene expression for its inflammatory skin disease pipeline test.
-
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference.
-
Castle Biosciences to Acquire AltheaDx
4/4/2022
Castle Biosciences, Inc. today announced it has signed a definitive agreement to acquire AltheaDx, Inc.
-
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
3/29/2022
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for Medicare & Medicaid Services (CMS) granted Advanced Diagnostic Laboratory Test (ADLT) status for the TissueCypher® Barrett’s Esophagus test, effective March 24, 2022.
-
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
3/25/2022
Castle Biosciences, Inc. today announced upcoming presentations on two of its skin cancer gene expression profile (GEP) tests at the 2022 American Academy of Dermatology.
-
Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
3/11/2022
Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx ® -Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity.
-
Castle Biosciences to Present at Upcoming Investor Conferences - Mar 01, 2022
3/1/2022
Castle Biosciences, Inc. announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the following upcoming investor conferences:
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results
2/28/2022
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.
-
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
2/14/2022
Castle Biosciences, Inc. today announced that it will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.
-
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/7/2022
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference.
-
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
2/3/2022
Castle Biosciences, Inc. today announced a collaboration with the National Cancer Institute (NCI) to link DecisionDx®-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program’s registries on cutaneous melanoma (CM) cases.
-
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
2/2/2022
Castle Biosciences, Inc. today announced that it has received a 2022 Top Workplaces USA award from Energage.
-
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
1/24/2022
Castle Biosciences, Inc., a leader in transforming disease management and improving patient outcomes through innovative diagnostics, will present data highlighting its portfolio of skin cancer tests at Maui Derm for Dermatologists 2022, being held Jan. 24-28, 2022, in Maui, Hawaii.
-
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
1/13/2022
Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced the publication of clinical performance study data demonstrating that DecisionDx®-SCC provides significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk).
-
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
1/12/2022
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UM Seq for Patients with Uveal Melanoma.
-
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
1/10/2022
Castle Biosciences, Inc. today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2021.
-
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
12/28/2021
Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 24th Annual Needham Growth Conference on Monday, Jan. 10, 2022, at 12:30 p.m. Eastern time.
-
Castle Biosciences Completes Acquisition of Cernostics
12/6/2021
Castle Biosciences, Inc. today announced it has completed its acquisition of Cernostics, Inc. (Cernostics).
-
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
11/24/2021
Castle Biosciences, Inc. today announced oral presentations on its DecisionDx® gene expression profile (GEP) tests for skin cancer at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting, held Nov. 19-21, 2021.